Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Fucà

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Journal for Immunotherapy of Cancer|June 24, 2021
Author response to Colle <i>et al</i>Giovanni Fucà, Francesca Corti, Filippo Pietrantonio
Current Opinion in Oncology|July 12, 2018
Immunotherapy-based combinations: an updateGiovanni Fucà, Filippo de Braud, Massimo Di Nicola
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
The clinical landscape of antibody-drug conjugates in endometrial cancerGiovanni Fucà, Ilaria Sabatucci, Mariachiara Paderno, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 29, 2024
The clinical landscape of antibody-drug conjugates in endometrial cancerGiovanni Fucà, Ilaria Sabatucci, Mariachiara Paderno, et al.
Expert Review of Anticancer Therapy|September 1, 2017
Castration-naive metastatic prostate cancer: reshaping old paradigmsRaffaele Ratta, Paolo Grassi, Giovanni Fucà, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2020
Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid TumorsGiovanni Fucà, Loic Reppel, Elisa Landoni, et al.
Expert Review of Clinical Pharmacology|September 29, 2017
Multimodal treatment of advanced renal cancer in 2017Alessia Mennitto, Elena Verzoni, Paolo Grassi, et al.
Cancers|August 7, 2021
Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against CancerFrancesco Mainini, Francesca De Santis, Giovanni Fucà, et al.
Therapeutic Advances in Medical Oncology|March 14, 2022
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implicationsFrancesca Ligorio, Luca Zambelli, Giovanni Fucà, et al.
Clinical Genitourinary Cancer|February 27, 2018
Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world AnalysisRaffaele Ratta, Elena Verzoni, Massimo Di Maio, et al.
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Journal for Immunotherapy of Cancer|June 24, 2021
Author response to Colle <i>et al</i>Giovanni Fucà, Francesca Corti, Filippo Pietrantonio
Current Opinion in Oncology|July 12, 2018
Immunotherapy-based combinations: an updateGiovanni Fucà, Filippo de Braud, Massimo Di Nicola
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
The clinical landscape of antibody-drug conjugates in endometrial cancerGiovanni Fucà, Ilaria Sabatucci, Mariachiara Paderno, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 29, 2024
The clinical landscape of antibody-drug conjugates in endometrial cancerGiovanni Fucà, Ilaria Sabatucci, Mariachiara Paderno, et al.
Expert Review of Anticancer Therapy|September 1, 2017
Castration-naive metastatic prostate cancer: reshaping old paradigmsRaffaele Ratta, Paolo Grassi, Giovanni Fucà, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2020
Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid TumorsGiovanni Fucà, Loic Reppel, Elisa Landoni, et al.
Expert Review of Clinical Pharmacology|September 29, 2017
Multimodal treatment of advanced renal cancer in 2017Alessia Mennitto, Elena Verzoni, Paolo Grassi, et al.
Cancers|August 7, 2021
Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against CancerFrancesco Mainini, Francesca De Santis, Giovanni Fucà, et al.
Therapeutic Advances in Medical Oncology|March 14, 2022
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implicationsFrancesca Ligorio, Luca Zambelli, Giovanni Fucà, et al.
Clinical Genitourinary Cancer|February 27, 2018
Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world AnalysisRaffaele Ratta, Elena Verzoni, Massimo Di Maio, et al.
Pageof 9